drugset / Trial / NCT06834490

Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia

NCT06834490

Phase 3 Completed 318 enrolled Pharmasoft
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).

Timeline

Start
2019-11-05
Primary completion
2020-12-08
Completion
2020-12-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator EMOXYPINE Small molecule 250 mg Intravenous

Indications